drugset / Trial / NCT00433095
Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
1st-line treatment of HER2/neu overexpressing breast cancer
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navelbine | Unknown | — | Oral |
| Subject | Trastuzumab | Monoclonal antibody | — | — |